Publication:

A clinical pharmacological experimental research analysis of the evidence-based rational pharmacotherapeutics of pefloxacin and newer quinolones

Background Pefloxacin is a newer broad-spectrum bactericidal fluoroquinolone antibiotic, with superior antibacterial activity in vivo against pathogenic ocular gram-negative and anaerobic microorganisms and better pharmacokinetic properties.

Methods 100 bacterial conjunctivitis patients were prescribed topical pefloxacin 0.3% ophthalmological drops monotherapy, 2 drops in each eye after every 3 hours for 2 days, and 2 drops in each eye after every 6 hours for next 5 days. The overall recovery of the patients was clinically examined and assessed. The patients who did not recover completely with 0.3% pefloxacin monotherapy ophthalmological drops, were administered topical pefloxacin 0.3% ophthalmological drops, 2 drops in each eye after every 6 hours for the next 3 days, as combination therapy, with other required ophthalmological eye drops, depending on the prognostic follow-up, on days 0, 3, 5, 7, 10, 15, 30, and on further follow-ups. The evidence-based rational pharmacotherapeutic patient percentage topical application requirements of 0.3% pefloxacin ophthalmological drops monotherapy and subsequent combination therapy for complete recovery from bacterial conjunctivitis was thoroughly analysed and assessed.

Results In this study, the patient percentage topical application requirements of pefloxacin 0.3% ophthalmological drops monotherapy and combination therapy in bacterial conjunctivitis patients showed that 93% patients had completely recovered with pefloxacin monotherapy, and 7% patients required pefloxacin combination therapy for complete recovery. The evidence-based rational pharmacotherapeutics of newer quinolones, in global multi-centre tertiary care hospitals, was also well characterized and analytically described.

Conclusions Therefore, 93% patients had completely recovered with the ocular antibiotic pefloxacin 0.3% ophthalmological drops monotherapy, and 7% patients required pefloxacin combination therapy for complete recovery. The evidence-based rational pharmacotherapeutics of newer quinolones was also distinctly delineated.